CMS NCD 259: Cardiointegram (CIG) Coverage Policy — What Billing Teams Need to Know in 2026

CMS updated National Coverage Determination 259 (NCD 259), governing the Cardiointegram (CIG) as an alternative to stress testing and thallium stress testing, effective March 12, 2026. This policy modification affects cardiology practices, diagnostic testing facilities, and any provider considering the CIG device as a non-invasive cardiac diagnostic tool. If your team has been submitting—or considering submitting—claims for CIG procedures, this policy has direct implications for your reimbursement strategy and denial exposure.

What Is a Cardiointegram and Why Does CMS NCD 259 Matter?

The Centers for Medicare & Medicaid Services defines the Cardiointegram device as a microcomputer-based system that receives output from a standard electrocardiogram (EKG) and transforms that signal into a graphic representation of heart electrophysiologic activity. The CIG is designed primarily as a substitute for Exercise Tolerance Testing with Thallium Imaging—a procedure used to identify changes in patients whose resting EKG is inadequate to detect coronary artery disease (CAD).

In practice, the CIG has been positioned as a less invasive, lower-burden alternative for patients who cannot safely undergo traditional stress testing. That clinical rationale is understandable—Exercise Tolerance Testing with Thallium Imaging carries patient risk and logistical complexity. The CIG's appeal is real. The coverage problem is also real.

Under NCD 259, CMS has consistently held that the CIG device remains investigational. The March 2026 modification does not reverse that position.

CMS Coverage Determination: CIG Is Non-Covered Under Medicare

The core holding of NCD 259 is unambiguous: Medicare program payment may not be made for the Cardiointegram at this time.

CMS's rationale rests on the device's investigational status. Specifically, CMS has determined that there is insufficient clinical data supporting the CIG's efficacy, sensitivity, and diagnostic value to justify coverage under the Medicare program. Until additional evidence satisfies CMS's clinical standards, the non-coverage determination stands.

This is an important distinction for billing teams to internalize. The CIG is not denied because it is inherently dangerous or lacks a theoretical basis—it is denied because the evidence base does not yet meet Medicare's threshold for clinical utility. That's a meaningful difference if your providers are advocating internally for the technology, but it doesn't change the billing outcome: claims will be denied.

The policy falls under the Diagnostic Tests (other) benefit category. CMS notes this may not represent an exhaustive list of applicable Medicare benefit categories for the item or service.

Medical Necessity Criteria Under NCD 259

Because the CIG carries a blanket non-coverage determination, there are no medical necessity criteria under which Medicare will approve a CIG claim. This is not a situation where documentation of coronary artery disease risk, prior authorization, or a specific diagnosis code unlocks coverage.

The non-coverage is absolute at the national level. There is no indication in NCD 259 of any coverage exceptions, no Local Coverage Determination (LCD) carve-outs referenced, and no prior authorization pathway that would convert a denied claim into an approved one.

For providers in specialties where the CIG has been marketed as a low-risk screening tool for CAD, that message needs to be communicated clearly: ordering a CIG for a Medicare patient does not carry a reimbursement pathway under current CMS policy.

Affected Codes

This policy does not list specific CPT or HCPCS codes. NCD 259 as modified does not assign a dedicated procedure code to the Cardiointegram service. There are no covered codes, no conditionally covered codes, and no associated ICD-10-CM diagnosis codes enumerated in the policy document.

What this means for billing: The absence of assigned codes doesn't create a workaround. Submitting CIG services under a related or analogous code (such as a standard EKG code) to obtain reimbursement for a non-covered service would constitute improper billing. If your team has questions about how CIG procedures have been coded in legacy claims, a compliance review is warranted.

The Investigational Designation: What It Means Clinically and Administratively

CMS uses the term "investigational" in a specific, consequential way. It means the technology has not demonstrated sufficient clinical efficacy through the evidence base CMS reviews—peer-reviewed literature, clinical trials, and specialty society guidance. It does not mean the device is unapproved by the FDA for other purposes, and it doesn't preclude use outside Medicare.

For revenue cycle teams, the practical impact of an investigational designation includes:

If a patient is informed and still wants the CIG procedure, providers may be able to collect from the patient directly—but only if proper ABN documentation is executed before the service is rendered. An ABN shifts financial liability to the patient when a service is expected to be denied as non-covered. Without an ABN on file, the provider may absorb the cost.

What Your Billing Team Should Do